Combination therapy for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of chemotherapy (GP), nimotuzumab, and sintilimab before standard treatment for locally advanced nasopharyngeal cancer. It aims to see if this approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of nasopharyngeal cancer called WHO type II or III that is locally advanced (stage III or IVa).
- You have not had treatment for this cancer yet, like radiation or chemotherapy.
- You are in generally good health, able to care for yourself, and have adequate organ function (kidneys, liver, blood counts).
- You do not have another active cancer or serious health problems like heart failure or uncontrolled diabetes.
- You are not pregnant and agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immune-based drugs (sintilimab and bevacizumab) plus standard chemotherapy for people with high-risk, locally advanced nasopharyngeal cancer that has spread to lymph nodes. The goal is to see if this approach works better than current treatments.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
This trial tests a combination of chemotherapy with two additional drugs (nimotuzumab and toripalimab) for people with advanced nasopharyngeal cancer that hasn't been treated yet. The goal is to see if this mix works better than standard therapy.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs—an anti-PD1 immunotherapy, nimotuzumab (targets EGFR), and capecitabine (chemotherapy)—for people whose nasopharyngeal cancer has returned or spread and no longer responds to platinum-based chemotherapy. The goal is to see if this combination can help when standard treatment stops working.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.